GHRP-6

Overview

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide and one of the earliest growth hormone secretagogues (GHS) developed. First synthesized by Cyril Bowers and colleagues in the 1980s, GHRP-6 was instrumental in the discovery and characterization of the growth hormone secretagogue receptor (GHS-R1a), which was later identified as the receptor for the endogenous hormone ghrelin.

GHRP-6 acts as a potent ghrelin mimetic, stimulating GH release from the anterior pituitary through the GHS-R1a receptor. However, unlike the more selective Ipamorelin developed later, GHRP-6 activates the ghrelin pathway broadly, producing notable secondary effects including pronounced appetite stimulation, elevation of cortisol and prolactin, and gastric motility changes.

The peptide played a foundational role in growth hormone secretagogue research. Bowers' work with GHRP-6 in the 1980s and 1990s established the concept that a distinct receptor pathway — separate from the GHRH receptor — could stimulate GH release. This ultimately led to the discovery of ghrelin itself in 1999 by Kojima et al., when the endogenous ligand for the GHS-R1a was finally identified.

Amino Acid Sequence

GHRP-6 is a hexapeptide with the following structure:

His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂

• Molecular formula: C₄₆H₅₆N₁₂O₆
• Molecular weight: 873.01 g/mol
• CAS Number: 87616-84-0

Structural features:

• D-Trp at position 2 and D-Phe at position 5 — D-amino acid substitutions confer resistance to enzymatic degradation
• C-terminal amidation — improves receptor binding and metabolic stability
• Two tryptophan residues — critical for GHS-R1a binding affinity

Mechanism of Action

GHS-R1a Receptor Activation

GHRP-6 is a potent agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a). Binding triggers:

• Activation of phospholipase C (PLC) and inositol trisphosphate (IP3) signaling
• Intracellular calcium release from the endoplasmic reticulum
• Protein kinase C (PKC) activation
• Exocytosis of GH-containing secretory vesicles from somatotroph cells

Appetite Stimulation (Orexigenic Effect)

GHRP-6 is the most orexigenic of the commonly studied GHRPs. This effect is mediated through:

• GHS-R1a activation in hypothalamic arcuate nucleus neurons
• Stimulation of neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons
• Mimicry of endogenous ghrelin's "hunger signal"

The appetite effect is dose-dependent and can be pronounced, typically peaking 20–30 minutes after injection and lasting 1–2 hours. This distinguishes GHRP-6 from Ipamorelin, which produces minimal appetite stimulation.

Cortisol and Prolactin Elevation

Unlike Ipamorelin, GHRP-6 produces measurable increases in:

• Cortisol — through activation of hypothalamic corticotropin-releasing hormone (CRH) pathways
• Prolactin — through direct or indirect effects on lactotroph cells
• ACTH — secondary to CRH stimulation

These elevations are dose-dependent and generally modest at standard research doses but represent a key differentiator from more selective GHRPs.

Somatostatin Suppression

GHRP-6 functionally antagonizes somatostatin's inhibitory effects on GH release. This occurs at both the hypothalamic and pituitary levels, allowing GH release even during periods of high somatostatin tone.

Gastric Motility and Gastroprotective Effects

GHRP-6 stimulates gastric motility through ghrelin receptor activation in the enteric nervous system. Interestingly, research has also demonstrated cytoprotective effects on gastric mucosa, with studies showing protection against ethanol-induced gastric lesions in animal models.

Research Summary

Pharmacokinetics

• Half-life: Approximately 15–60 minutes (varies by source; shorter than Ipamorelin)
• Onset of action: GH elevation detectable within 10–15 minutes of subcutaneous administration
• Peak GH levels: 15–30 minutes post-injection
• Duration of GH elevation: 1.5–3 hours
• Appetite onset: 15–20 minutes post-injection, lasting 1–2 hours
• Route: Subcutaneous injection (primary); intravenous (research settings); intranasal (studied but low bioavailability)
• Metabolism: Rapid hepatic and renal clearance; D-amino acid substitutions provide moderate protease resistance
• Food interaction: GH response is significantly blunted by recent food intake, particularly fats and carbohydrates; fasting administration is standard in research protocols

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Dosing Schedule

Syringe Measurements (U-100 insulin syringe)

Cycle Guidelines

• Cycle length: 8-12 weeks
• Route: Subcutaneous injection
• Timing: 3 injections daily spaced 4+ hours apart (e.g., morning, midday, bedtime)
• Fasting: Administer on an empty stomach (2-3 hours after meals, 30 minutes before eating)
• Injection sites: Rotate between abdomen, thighs, and upper arms
• Note: GHRP-6 produces strong hunger (ghrelin-mimetic effect); plan meals accordingly

Common Discussion Topics

1. Appetite effects — GHRP-6's pronounced hunger stimulation is both its most discussed advantage (for those seeking weight gain or appetite recovery) and its most cited drawback (for those seeking lean body composition improvements).

2. GHRP-6 vs. Ipamorelin — The selectivity trade-off is a central discussion point. GHRP-6 produces comparable or slightly greater GH release than Ipamorelin but with cortisol, prolactin, and appetite effects that Ipamorelin largely avoids.

3. Combination with CJC-1295 — Like other GHRPs, GHRP-6 is frequently combined with GHRH analogs such as CJC-1295 no DAC for synergistic GH release.

4. Historical significance — GHRP-6's role in the discovery of the ghrelin receptor and, indirectly, ghrelin itself, makes it a historically important compound in endocrinology.

5. Cardioprotective research — Studies showing reduced infarct size in ischemia-reperfusion models generate interest beyond the GH secretagogue community.

6. Desensitization — Concerns about GHS-R1a desensitization with chronic use are discussed, with some protocols recommending cycling or dose variation.

Related Compounds

• GHRP-2 — a more potent GHRP with less appetite stimulation than GHRP-6 but more cortisol/prolactin effects than Ipamorelin
• Ipamorelin — the most selective GHRP; comparable GH release with minimal secondary hormonal effects
• CJC-1295 — a GHRH analog commonly paired with GHRPs for synergistic GH release
• Sermorelin — an earlier GHRH analog; alternative to CJC-1295 for the GHRH component of combination protocols
• Hexarelin — the most potent GHRP by peak GH amplitude; significant cortisol and prolactin elevation
• Ghrelin — the endogenous hormone that GHRP-6 mimics; identified through GHRP-6-driven receptor research